{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:17:26Z","timestamp":1778221046887,"version":"3.51.4"},"reference-count":266,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100010564","name":"Academic Medical Organization of Southwestern Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019188","name":"HORIZON EUROPE Excellent Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016382","name":"Schmidt Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016382","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GSK Chair in Clinical Pharmacology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Proteom"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1186\/s12014-026-09601-8","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T12:50:07Z","timestamp":1775566207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Computational proteomics to enhance personalized treatment of COVID-19 and Long COVID"],"prefix":"10.1186","volume":"23","author":[{"given":"Debasis","family":"Sahu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Logan R.","family":"Van Nynatten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Tweddell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Daley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas D.","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"9601_CR1","unstructured":"Organization WH. COVID\u201319 cases | WHO COVID\u201319 dashboard n.d. [Available from: https:\/\/data.who.int\/dashboards\/covid19\/cases?n=c"},{"issue":"1","key":"9601_CR2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12931-025-03200-1","volume":"26","author":"T Cruz","year":"2025","unstructured":"Cruz T, Albacar N, Ruiz E, Lledo GM, Perea L, Puebla A, et al. Persistence of dysfunctional immune response 12 months after SARS-CoV-2 infection and their relationship with pulmonary sequelae and long COVID. Respir Res. 2025;26(1):152.","journal-title":"Respir Res"},{"key":"9601_CR3","volume-title":"StatPearls","author":"M Cascella","year":"2025","unstructured":"Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2025, StatPearls Publishing LLC.; 2025."},{"issue":"12","key":"9601_CR4","doi-asserted-by":"publisher","first-page":"5279","DOI":"10.1021\/acs.jproteome.4c00586","volume":"23","author":"PE Geyer","year":"2024","unstructured":"Geyer PE, Hornburg D, Pernemalm M, Hauck SM, Palaniappan KK, Albrecht V, et al. The Circulating ProteomeTechnological Developments, Current Challenges, and Future Trends. J Proteome Res. 2024;23(12):5279\u201395.","journal-title":"J Proteome Res"},{"issue":"1","key":"9601_CR5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12931-025-03331-5","volume":"26","author":"DD Fraser","year":"2025","unstructured":"Fraser DD, Van Nynatten LR, Tweddell D, Daley M, Russell JA, CAPtivate Consortium. Divergent biological pathways distinguish community-acquired pneumonia from COVID-19 despite similar plasma cytokine profiles. Respir Res. 2025;26(1):264.","journal-title":"Respir Res"},{"issue":"4","key":"9601_CR6","doi-asserted-by":"publisher","first-page":"e00519","DOI":"10.1128\/mbio.00519-22","volume":"13","author":"M Yamamoto","year":"2022","unstructured":"Yamamoto M, Gohda J, Kobayashi A, Tomita K, Hirayama Y, Koshikawa N, et al. Metalloproteinase-dependent and TMPRSS2-independent cell surface entry pathway of SARS-CoV-2 requires the furin cleavage site and the S2 domain of spike protein. mBio. 2022;13(4):e00519-22.","journal-title":"mBio"},{"issue":"4","key":"9601_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10238-020-00648-x","volume":"20","author":"M Gavriatopoulou","year":"2020","unstructured":"Gavriatopoulou M, Korompoki E, Fotiou D, Ntanasis-Stathopoulos I, Psaltopoulou T, Kastritis E, et al. Organ-specific manifestations of COVID-19 infection. Clin Exp Med. 2020;20(4):493\u2013506.","journal-title":"Clin Exp Med"},{"issue":"1","key":"9601_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41572-025-00674-7","volume":"11","author":"JE Wilson","year":"2025","unstructured":"Wilson JE, Gurdasani D, Helbok R, Ozturk S, Fraser DD, Filipovic SR, et al. COVID-19-associated neurological and psychological manifestations. Nat Rev Dis Primers. 2025;11(1):91.","journal-title":"Nat Rev Dis Primers"},{"issue":"1Supplement","key":"9601_CR9","doi-asserted-by":"publisher","first-page":"7525","DOI":"10.4049\/jimmunol.210.Supp.75.25","volume":"210","author":"DS Gibson","year":"2023","unstructured":"Gibson DS, McLaughlin J, McDaid D, Lynch S, OKane M, Kelly M, et al. Inflammatory and immune response signatures associated with COVID-19 severity. J Immunol. 2023;210(1Supplement):7525\u20137525.","journal-title":"J Immunol"},{"issue":"2","key":"9601_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/pathophysiology28020014","volume":"28","author":"DD Fraser","year":"2021","unstructured":"Fraser DD, Cepinskas G, Slessarev M, Martin CM, Daley M, Patel MA, et al. Critically Ill COVID-19 Patients Exhibit Anti-SARS-CoV-2 Serological Responses. Pathophysiology. 2021;28(2):212\u201323.","journal-title":"Pathophysiology"},{"issue":"3","key":"9601_CR11","volume":"3","author":"DD Fraser","year":"2021","unstructured":"Fraser DD, Cepinskas G, Slessarev M, Martin CM, Daley M, Patel MA, et al. Detection and profiling of human coronavirus immunoglobulins in critically ill coronavirus disease 2019 patients. Crit Care Explor. 2021;3(3):e0369.","journal-title":"Crit Care Explor"},{"issue":"1","key":"9601_CR12","doi-asserted-by":"publisher","first-page":"e12704","DOI":"10.1016\/j.heliyon.2022.e12704","volume":"9","author":"DD Fraser","year":"2023","unstructured":"Fraser DD, Patel MA, Van Nynatten LR, Martin C, Seney SL, Miller MR, et al. Cross-immunity against SARS-COV-2 variants of concern in naturally infected critically ill COVID-19 patients. Heliyon. 2023;9(1):e12704.","journal-title":"Heliyon"},{"key":"9601_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/v13101911","author":"E Torbati","year":"2021","unstructured":"Torbati E, Krause KL, Ussher JE. The immune response to SARS-CoV-2 and variants of concern. Viruses. 2021;13(10):1911. https:\/\/doi.org\/10.3390\/v13101911.","journal-title":"Viruses"},{"issue":"1","key":"9601_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-95956-1","volume":"15","author":"DD Fraser","year":"2025","unstructured":"Fraser DD, Singh D, Cela E, Patel MA, Assaf M, Quintero M, et al. Neutralizing antibodies to SARS-CoV-2 variants of concern: a pediatric surveillance study. Sci Rep. 2025;15(1):11588.","journal-title":"Sci Rep"},{"key":"9601_CR15","doi-asserted-by":"crossref","unstructured":"Baj J, Karakula-Juchnowicz H, Teresinski G, Buszewicz G, Ciesielka M, Sitarz R et al. COVID-19: Specific and Non-Specific Clinical Manifestations and Symptoms: The Current State of Knowledge. J Clin Med. 2020;9(6):1753.","DOI":"10.3390\/jcm9061753"},{"issue":"2","key":"9601_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41423-024-01127-z","volume":"21","author":"N Le Bert","year":"2024","unstructured":"Le Bert N, Samandari T. Silent battles: immune responses in asymptomatic SARS-CoV-2 infection. Cell Mol Immunol. 2024;21(2):159\u201370.","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"9601_CR17","volume":"2","author":"DD Fraser","year":"2020","unstructured":"Fraser DD, Cepinskas G, Slessarev M, Martin C, Daley M, Miller MR, et al. Inflammation profiling of critically ill coronavirus disease 2019 patients. Crit Care Explor. 2020;2(6):e0144.","journal-title":"Crit Care Explor"},{"issue":"12","key":"9601_CR18","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.3390\/v13122456","volume":"13","author":"W Bauer","year":"2021","unstructured":"Bauer W, Weber M, Diehl-Wiesenecker E, Galtung N, Prpic M, Somasundaram R, et al. Plasma Proteome Fingerprints Reveal Distinctiveness and Clinical Outcome of SARS-CoV-2 Infection. Viruses. 2021;13(12):2456.","journal-title":"Viruses"},{"key":"9601_CR19","doi-asserted-by":"publisher","first-page":"592727","DOI":"10.3389\/fimmu.2021.592727","volume":"12","author":"E Mortaz","year":"2021","unstructured":"Mortaz E, Tabarsi P, Jamaati H, Dalil Roofchayee N, Dezfuli NK, Hashemian SM, et al. Increased Serum Levels of Soluble TNF-\u03b1 Receptor Is Associated With ICU Mortality in COVID-19 Patients. Front Immunol. 2021;12:592727.","journal-title":"Front Immunol"},{"key":"9601_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107331","volume":"217","author":"N Keur","year":"2023","unstructured":"Keur N, Saridaki M, Ricano-Ponce I, Netea MG, Giamarellos-Bourboulis EJ, Kumar V. Analysis of inflammatory protein profiles in the circulation of COVID-19 patients identifies patients with severe disease phenotypes. Respir Med. 2023;217:107331.","journal-title":"Respir Med"},{"issue":"1","key":"9601_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-023-02364-y","volume":"24","author":"LM Palma Medina","year":"2023","unstructured":"Palma Medina LM, Babacic H, Dzidic M, Parke A, Garcia M, Maleki KT, et al. Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumonia. Respir Res. 2023;24(1):62.","journal-title":"Respir Res"},{"key":"9601_CR22","doi-asserted-by":"publisher","first-page":"781100","DOI":"10.3389\/fimmu.2021.781100","volume":"12","author":"K Suhre","year":"2021","unstructured":"Suhre K, Sarwath H, Engelke R, Sohail MU, Cho SJ, Whalen W, et al. Identification of Robust Protein Associations With COVID-19 Disease Based on Five Clinical Studies. Front Immunol. 2021;12:781100.","journal-title":"Front Immunol"},{"issue":"1","key":"9601_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00753-7","volume":"6","author":"XN Zhao","year":"2021","unstructured":"Zhao XN, You Y, Cui XM, Gao HX, Wang GL, Zhang SB, et al. Single-cell immune profiling reveals distinct immune response in asymptomatic COVID-19 patients. Signal Transduct Target Ther. 2021;6(1):342.","journal-title":"Signal Transduct Target Ther"},{"key":"9601_CR24","doi-asserted-by":"publisher","first-page":"821730","DOI":"10.3389\/fimmu.2022.821730","volume":"13","author":"A Soares-Schanoski","year":"2022","unstructured":"Soares-Schanoski A, Sauerwald N, Goforth CW, Periasamy S, Weir DL, Lizewski S, et al. Asymptomatic SARS-CoV-2 Infection Is Associated With Higher Levels of Serum IL-17\u00a0C, Matrix Metalloproteinase 10 and Fibroblast Growth Factors Than Mild Symptomatic COVID-19. Front Immunol. 2022;13:821730.","journal-title":"Front Immunol"},{"key":"9601_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109177","volume":"245","author":"M Alahdal","year":"2022","unstructured":"Alahdal M, Elkord E. Exhaustion and over-activation of immune cells in COVID-19: challenges and therapeutic opportunities. Clin Immunol. 2022;245:109177.","journal-title":"Clin Immunol"},{"key":"9601_CR26","doi-asserted-by":"publisher","first-page":"1077236","DOI":"10.3389\/fimmu.2023.1077236","volume":"14","author":"H Nasrollahi","year":"2023","unstructured":"Nasrollahi H, Talepoor AG, Saleh Z, Eshkevar Vakili M, Heydarinezhad P, Karami N, et al. Immune responses in mildly versus critically ill COVID-19 patients. Front Immunol. 2023;14:1077236.","journal-title":"Front Immunol"},{"issue":"1","key":"9601_CR27","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1038\/s41467-020-17240-2","volume":"11","author":"JW Song","year":"2020","unstructured":"Song JW, Zhang C, Fan X, Meng FP, Xu Z, Xia P, et al. Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nat Commun. 2020;11(1):3410.","journal-title":"Nat Commun"},{"issue":"9","key":"9601_CR28","volume":"2","author":"DD Fraser","year":"2020","unstructured":"Fraser DD, Cepinskas G, Patterson EK, Slessarev M, Martin C, Daley M, et al. Novel outcome biomarkers identified with targeted proteomic analyses of plasma from critically ill coronavirus disease 2019 patients. Crit Care Explor. 2020;2(9):e0189.","journal-title":"Crit Care Explor"},{"issue":"1","key":"9601_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85877-0","volume":"11","author":"H Patel","year":"2021","unstructured":"Patel H, Ashton NJ, Dobson RJB, Andersson LM, Yilmaz A, Blennow K, et al. Proteomic blood profiling in mild, severe and critical COVID-19 patients. Sci Rep. 2021;11(1):6357.","journal-title":"Sci Rep"},{"key":"9601_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2022.105416","volume":"164","author":"E Hazrati","year":"2022","unstructured":"Hazrati E, Gholami M, Farahani RH, Ghorban K, Ghayomzadeh M, Rouzbahani NH. The effect of IGF-1 plasma concentration on COVID-19 severity. Microb Pathog. 2022;164:105416.","journal-title":"Microb Pathog"},{"issue":"1","key":"9601_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s43856-023-00283-z","volume":"3","author":"K Hufnagel","year":"2023","unstructured":"Hufnagel K, Fathi A, Stroh N, Klein M, Skwirblies F, Girgis R, et al. Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Commun Med (Lond). 2023;3(1):51.","journal-title":"Commun Med (Lond)"},{"issue":"Pt 1","key":"9601_CR32","doi-asserted-by":"publisher","first-page":"125295","DOI":"10.1016\/j.talanta.2023.125295","volume":"268","author":"S Kugler","year":"2024","unstructured":"Kugler S, Hahnefeld L, Kloka JA, Ginzel S, Nurenberg-Goloub E, Zinn S, et al. Short-term predictor for COVID-19 severity from a longitudinal multi-omics study for practical application in intensive care units. Talanta. 2024;268(Pt 1):125295.","journal-title":"Talanta"},{"key":"9601_CR33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176640","author":"JP Gygi","year":"2024","unstructured":"Gygi JP, Maguire C, Patel RK, Shinde P, Konstorum A, Shannon CP, et al. Integrated longitudinal multiomics study identifies immune programs associated with acute COVID-19 severity and mortality. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI176640.","journal-title":"J Clin Invest"},{"issue":"5","key":"9601_CR34","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1164\/rccm.202106-1514OC","volume":"205","author":"DE Leisman","year":"2022","unstructured":"Leisman DE, Mehta A, Thompson BT, Charland NC, Gonye ALK, Gushterova I, et al. Alveolar, Endothelial, and Organ Injury Marker Dynamics in Severe COVID-19. Am J Respir Crit Care Med. 2022;205(5):507\u201319.","journal-title":"Am J Respir Crit Care Med"},{"key":"9601_CR35","doi-asserted-by":"publisher","first-page":"106147","DOI":"10.1016\/j.nbd.2023.106147","volume":"182","author":"O El-Agnaf","year":"2023","unstructured":"El-Agnaf O, Bensmail I, Al-Nesf MAY, Flynn J, Taylor M, Majbour NK, et al. Uncovering a neurological protein signature for severe COVID-19. Neurobiol Dis. 2023;182:106147.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"9601_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04149-9","volume":"21","author":"C Iosef","year":"2023","unstructured":"Iosef C, Knauer MJ, Nicholson M, Van Nynatten LR, Cepinskas G, Draghici S, et al. Plasma proteome of long-COVID patients indicates HIF-mediated vasculo-proliferative disease with impact on brain and heart function. J Transl Med. 2023;21(1):377.","journal-title":"J Transl Med"},{"issue":"5","key":"9601_CR37","doi-asserted-by":"publisher","first-page":"100287","DOI":"10.1016\/j.xcrm.2021.100287","volume":"2","author":"MR Filbin","year":"2021","unstructured":"Filbin MR, Mehta A, Schneider AM, Kays KR, Guess JR, Gentili M, et al. Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep Med. 2021;2(5):100287.","journal-title":"Cell Rep Med"},{"issue":"6","key":"9601_CR38","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.cell.2020.08.002","volume":"182","author":"A Silvin","year":"2020","unstructured":"Silvin A, Chapuis N, Dunsmore G, Goubet AG, Dubuisson A, Derosa L, et al. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell. 2020;182(6):1401-18 e18.","journal-title":"Cell"},{"key":"9601_CR39","doi-asserted-by":"crossref","unstructured":"Laudanski K, Jihane H, Antalosky B, Ghani D, Phan U, Hernandez R et al. Unbiased Analysis of Temporal Changes in Immune Serum Markers in Acute COVID-19 Infection With Emphasis on Organ Failure, Anti-Viral Treatment, and Demographic Characteristics. Front Immunol. 2021;Volume 12:650465. .","DOI":"10.3389\/fimmu.2021.650465"},{"key":"9601_CR40","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.64827","author":"J Gisby","year":"2021","unstructured":"Gisby J, Clarke CL, Medjeral-Thomas N, Malik TH, Papadaki A, Mortimer PM, et al. Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death. Elife. 2021. https:\/\/doi.org\/10.7554\/eLife.64827.","journal-title":"Elife"},{"issue":"1","key":"9601_CR41","doi-asserted-by":"publisher","first-page":"7775","DOI":"10.1038\/s41467-022-35454-4","volume":"13","author":"JS Gisby","year":"2022","unstructured":"Gisby JS, Buang NB, Papadaki A, Clarke CL, Malik TH, Medjeral-Thomas N, et al. Multi-omics identify falling LRRC15 as a COVID-19 severity marker and persistent pro-thrombotic signals in convalescence. Nat Commun. 2022;13(1):7775.","journal-title":"Nat Commun"},{"key":"9601_CR42","doi-asserted-by":"crossref","unstructured":"Rando HM, Bennett TD, Byrd JB, Bramante C, Callahan TJ, Chute CG et al. Challenges in defining Long COVID: Striking differences across literature, Electronic Health Records, and patient-reported information. medRxiv [Preprint]. 2021.Mar 26:2021.03.20.21253896.","DOI":"10.1101\/2021.03.20.21253896"},{"issue":"1","key":"9601_CR43","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/cid\/ciaa964","volume":"74","author":"C Garcia-Vidal","year":"2022","unstructured":"Garcia-Vidal C, Moreno-Garcia E, Hernandez-Meneses M, Puerta-Alcalde P, Chumbita M, Garcia-Pouton N, et al. Personalized Therapy Approach for Hospitalized Patients with Coronavirus Disease 2019. Clin Infect Dis. 2022;74(1):127\u201332.","journal-title":"Clin Infect Dis"},{"key":"9601_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110698","volume":"131","author":"E Nasonov","year":"2020","unstructured":"Nasonov E, Samsonov M. The role of interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020;131:110698.","journal-title":"Biomed Pharmacother"},{"key":"9601_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.795315","volume":"13","author":"G Zizzo","year":"2022","unstructured":"Zizzo G, Tamburello A, Castelnovo L, Laria A, Mumoli N, Faggioli PM, et al. Immunotherapy of COVID-19: inside and beyond IL-6 signalling. Front Immunol. 2022;13:795315.","journal-title":"Front Immunol"},{"key":"9601_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14090911","author":"DE Man","year":"2024","unstructured":"Man DE, Andor M, Buda V, Kundnani NR, Duda-Seiman DM, Craciun LM, et al. Insulin resistance in long COVID-19 syndrome. J Pers Med. 2024. https:\/\/doi.org\/10.3390\/jpm14090911.","journal-title":"J Pers Med"},{"issue":"1","key":"9601_CR47","doi-asserted-by":"publisher","first-page":"E43","DOI":"10.1152\/ajpendo.00219.2020","volume":"319","author":"J Mori","year":"2020","unstructured":"Mori J, Oudit GY, Lopaschuk GD. SARS-CoV-2 perturbs the renin-angiotensin system and energy metabolism. Am J Physiol Endocrinol Metab. 2020;319(1):E43-e7.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"9601_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9050556","author":"D Barh","year":"2021","unstructured":"Barh D, Aljabali AA, Tambuwala MM, Tiwari S, Serrano-Aroca A, Alzahrani KJ, et al. Predicting COVID-19-comorbidity pathway crosstalk-based targets and drugs: towards personalized COVID-19 management. Biomedicines. 2021. https:\/\/doi.org\/10.3390\/biomedicines9050556.","journal-title":"Biomedicines"},{"issue":"6","key":"9601_CR49","doi-asserted-by":"publisher","first-page":"6563","DOI":"10.1007\/s11357-024-01227-8","volume":"46","author":"SJ Russell","year":"2024","unstructured":"Russell SJ, Parker K, Lehoczki A, Lieberman D, Partha IS, Scott SJ, et al. Post-acute sequelae of SARS-CoV-2 infection (long COVID) in older adults. Geroscience. 2024;46(6):6563\u201381.","journal-title":"Geroscience"},{"key":"9601_CR50","doi-asserted-by":"publisher","DOI":"10.1177\/20503121231194400","volume":"11","author":"AR Joffe","year":"2023","unstructured":"Joffe AR, Elliott A. Long COVID as a functional somatic symptom disorder caused by abnormally precise prior expectations during Bayesian perceptual processing: a new hypothesis and implications for pandemic response. SAGE Open Med. 2023;11:20503121231194400.","journal-title":"SAGE Open Med"},{"key":"9601_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13020334","author":"V Conti","year":"2023","unstructured":"Conti V, Corbi G, Sabbatino F, De Pascale D, Sellitto C, Stefanelli B, et al. Long COVID: clinical framing, biomarkers, and therapeutic approaches. J Pers Med. 2023. https:\/\/doi.org\/10.3390\/jpm13020334.","journal-title":"J Pers Med"},{"issue":"12","key":"9601_CR52","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.mayocp.2021.06.027","volume":"96","author":"M Prasad","year":"2021","unstructured":"Prasad M, Leon M, Lerman LO, Lerman A. Viral endothelial dysfunction: a unifying mechanism for COVID-19. Mayo Clin Proc. 2021;96(12):3099\u2013108.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"9601_CR53","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41590-023-01724-6","volume":"25","author":"K Yin","year":"2024","unstructured":"Yin K, Peluso MJ, Luo X, Thomas R, Shin MG, Neidleman J, et al. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nat Immunol. 2024;25(2):218\u201325.","journal-title":"Nat Immunol"},{"issue":"1","key":"9601_CR54","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41590-025-02353-x","volume":"27","author":"M Aid","year":"2026","unstructured":"Aid M, Boero-Teyssier V, McMahan K, Dang R, Doyle M, Belabbaci N, et al. Long COVID involves activation of proinflammatory and immune exhaustion pathways. Nat Immunol. 2026;27(1):61\u201371.","journal-title":"Nat Immunol"},{"issue":"5","key":"9601_CR55","doi-asserted-by":"publisher","first-page":"e2200031","DOI":"10.1002\/prca.202200031","volume":"16","author":"J Zhao","year":"2022","unstructured":"Zhao J, Schank M, Wang L, Dang X, Cao D, Khanal S, et al. Plasma biomarkers for systemic inflammation in COVID-19 survivors. Proteom Clin Appl. 2022;16(5):e2200031.","journal-title":"Proteom Clin Appl"},{"key":"9601_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1027122","volume":"13","author":"M Zoodsma","year":"2022","unstructured":"Zoodsma M, de Nooijer AH, Grondman I, Gupta MK, Bonifacius A, Koeken V, et al. Targeted proteomics identifies circulating biomarkers associated with active COVID-19 and post-COVID-19. Front Immunol. 2022;13:1027122.","journal-title":"Front Immunol"},{"issue":"1","key":"9601_CR57","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1038\/s41467-023-38682-4","volume":"14","author":"A Talla","year":"2023","unstructured":"Talla A, Vasaikar SV, Szeto GL, Lemos MP, Czartoski JL, MacMillan H, et al. Persistent serum protein signatures define an inflammatory subcategory of long COVID. Nat Commun. 2023;14(1):3417.","journal-title":"Nat Commun"},{"key":"9601_CR58","volume-title":"Chronic Inflammation. StatPearls","author":"R Pahwa","year":"2025","unstructured":"Pahwa R, Goyal A, Jialal I. Chronic Inflammation. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2025, StatPearls Publishing LLC.; 2025."},{"key":"9601_CR59","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.yjmcc.2021.11.010","volume":"164","author":"Z Ma","year":"2022","unstructured":"Ma Z, Yang KY, Huang Y, Lui KO. Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications. J Mol Cell Cardiol. 2022;164:69\u201382.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"9601_CR60","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/jcmm.17622","volume":"27","author":"C Iosef","year":"2023","unstructured":"Iosef C, Martin CM, Slessarev M, Gillio-Meina C, Cepinskas G, Han VKM, et al. COVID-19 plasma proteome reveals novel temporal and cell-specific signatures for disease severity and high-precision disease management. J Cell Mol Med. 2023;27(1):141\u201357.","journal-title":"J Cell Mol Med"},{"key":"9601_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1254310","volume":"14","author":"A Shafqat","year":"2023","unstructured":"Shafqat A, Omer MH, Albalkhi I, Alabdul Razzak G, Abdulkader H, Abdul Rab S, et al. Neutrophil extracellular traps and long COVID. Front Immunol. 2023;14:1254310.","journal-title":"Front Immunol"},{"issue":"1","key":"9601_CR62","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s10020-022-00548-8","volume":"28","author":"MA Patel","year":"2022","unstructured":"Patel MA, Knauer MJ, Nicholson M, Daley M, Van Nynatten LR, Martin C, et al. Elevated vascular transformation blood biomarkers in Long-COVID indicate angiogenesis as a key pathophysiological mechanism. Mol Med. 2022;28(1):122.","journal-title":"Mol Med"},{"issue":"1","key":"9601_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12014-023-09436-7","volume":"20","author":"E Yamga","year":"2023","unstructured":"Yamga E, Soule A, Piche A, Emad A, Durand M, Rousseau S. Validation of ANG-1 and P-SEL as biomarkers of post-COVID-19 conditions using data from the Biobanque quebecoise de la COVID-19 (BQC-19). Clin Proteomics. 2023;20(1):44.","journal-title":"Clin Proteomics"},{"issue":"1","key":"9601_CR64","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10456-023-09890-9","volume":"27","author":"A Philippe","year":"2024","unstructured":"Philippe A, Gunther S, Rancic J, Cavagna P, Renaud B, Gendron N, et al. VEGF-A plasma levels are associated with impaired DLCO and radiological sequelae in long COVID patients. Angiogenesis. 2024;27(1):51\u201366.","journal-title":"Angiogenesis"},{"issue":"1","key":"9601_CR65","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10020-023-00610-z","volume":"29","author":"MA Patel","year":"2023","unstructured":"Patel MA, Knauer MJ, Nicholson M, Daley M, Van Nynatten LR, Cepinskas G, et al. Organ and cell-specific biomarkers of Long-COVID identified with targeted proteomics and machine learning. Mol Med. 2023;29(1):26.","journal-title":"Mol Med"},{"issue":"3","key":"9601_CR66","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133\u201346.","journal-title":"Nat Rev Microbiol"},{"key":"9601_CR67","doi-asserted-by":"publisher","first-page":"199363","DOI":"10.1016\/j.virusres.2024.199363","volume":"344","author":"T Schmitz","year":"2024","unstructured":"Schmitz T, Freuer D, Gosslau Y, Warm TD, Hyhlik-Durr A, Linseisen J, et al. Can inflammatory plasma proteins predict Long COVID or Fatigue severity after SARS-CoV-2 infection? Virus Res. 2024;344:199363.","journal-title":"Virus Res"},{"issue":"4","key":"9601_CR68","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41590-024-01778-0","volume":"25","author":"F Liew","year":"2024","unstructured":"Liew F, Efstathiou C, Fontanella S, Richardson M, Saunders R, Swieboda D, et al. Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nat Immunol. 2024;25(4):607\u201321.","journal-title":"Nat Immunol"},{"issue":"1","key":"9601_CR69","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41591-022-02116-3","volume":"29","author":"H Zhang","year":"2023","unstructured":"Zhang H, Zang C, Xu Z, Zhang Y, Xu J, Bian J, et al. Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat Med. 2023;29(1):226\u201335.","journal-title":"Nat Med"},{"issue":"1","key":"9601_CR70","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41591-022-02130-5","volume":"29","author":"Machine learning identifies","year":"2023","unstructured":"Machine learning identifies. long COVID patterns from electronic health records. Nat Med. 2023;29(1):47\u20138.","journal-title":"Nat Med"},{"key":"9601_CR71","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01768-2020","author":"LDJ Bos","year":"2020","unstructured":"Bos LDJ, Sinha P, Dickson RP. The perils of premature phenotyping in COVID-19: a call for caution. Eur Respir J. 2020. https:\/\/doi.org\/10.1183\/13993003.01768-2020.","journal-title":"Eur Respir J"},{"issue":"6","key":"9601_CR72","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-2600(20)30124-7","volume":"8","author":"K Reddy","year":"2020","unstructured":"Reddy K, Sinha P, O\u2019Kane CM, Gordon AC, Calfee CS, McAuley DF. Subphenotypes in critical care: translation into clinical practice. Lancet Respir Med. 2020;8(6):631\u201343.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"9601_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109536","volume":"27","author":"S Padilla","year":"2024","unstructured":"Padilla S, Ledesma C, Garcia-Abellan J, Garcia JA, Fernandez-Gonzalez M, de la Rica A, et al. Long COVID across SARS-CoV-2 variants, lineages, and sublineages. iScience. 2024;27(4):109536.","journal-title":"iScience"},{"issue":"4","key":"9601_CR74","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/all.16526","volume":"80","author":"N Baalbaki","year":"2025","unstructured":"Baalbaki N, Slob EMA, Kazer SW, M IA-A, Bogaard HJ, Golebski K, et al. The Omics Landscape of Long COVID-A Comprehensive Systematic Review to Advance Biomarker, Target and Drug Discovery. Allergy. 2025;80(4):932\u201348.","journal-title":"Allergy"},{"issue":"7","key":"9601_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110344","volume":"27","author":"J Wang","year":"2024","unstructured":"Wang J, Liang X, Zheng Y, Zhu Y, Zhou K, Wu X, et al. Pulmonary and renal long COVID at two-year revisit. iScience. 2024;27(7):110344.","journal-title":"iScience"},{"issue":"1","key":"9601_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01640-z","volume":"8","author":"J Li","year":"2023","unstructured":"Li J, Zhou Y, Ma J, Zhang Q, Shao J, Liang S, et al. The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID. Signal Transduct Target Ther. 2023;8(1):416.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"9601_CR77","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12916-025-03971-w","volume":"23","author":"H Yang","year":"2025","unstructured":"Yang H, Guan L, Xue Y, Li X, Gao L, Zhang Z, et al. Longitudinal multi-omics analysis of convalescent individuals with respiratory sequelae 6\u201336 months after COVID-19. BMC Med. 2025;23(1):134.","journal-title":"BMC Med"},{"key":"9601_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.117855","volume":"183","author":"HX Lim","year":"2025","unstructured":"Lim HX, Khalid K, Abdullah ADI, Lee LH, Raja Ali RA. Subphenotypes of long COVID and the clinical applications of probiotics. Biomed Pharmacother. 2025;183:117855.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"9601_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.315","volume":"4","author":"C Chen","year":"2023","unstructured":"Chen C, Wang J, Pan D, Wang X, Xu Y, Yan J, et al. Applications of multi-omics analysis in human diseases. MedComm. 2023;4(4):e315.","journal-title":"MedComm"},{"issue":"1","key":"9601_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-017-0045-9","volume":"4","author":"S Delhalle","year":"2018","unstructured":"Delhalle S, Bode SFN, Balling R, Ollert M, He FQ. A roadmap towards personalized immunology. NPJ Syst Biol Appl. 2018;4(1):9.","journal-title":"NPJ Syst Biol Appl"},{"issue":"12","key":"9601_CR81","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1021\/acs.jproteome.1c00657","volume":"20","author":"EW Deutsch","year":"2021","unstructured":"Deutsch EW, Omenn GS, Sun Z, Maes M, Pernemalm M, Palaniappan KK, et al. Advances and Utility of the Human Plasma Proteome. J Proteome Res. 2021;20(12):5241\u201363.","journal-title":"J Proteome Res"},{"issue":"5","key":"9601_CR82","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.immuni.2020.10.008","volume":"53","author":"T Shu","year":"2020","unstructured":"Shu T, Ning W, Wu D, Xu J, Han Q, Huang M, et al. Plasma proteomics identify biomarkers and pathogenesis of COVID-19. Immunity. 2020;53(5):1108-22.e5.","journal-title":"Immunity"},{"key":"9601_CR83","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/978-1-0716-4462-1_12","volume":"2914","author":"M Boluda-Navarro","year":"2025","unstructured":"Boluda-Navarro M. Olink(\u00ae) explore for high-throughput protein biomarker discovery in cerebrospinal fluid. Methods Mol Biol. 2025;2914:141\u201363.","journal-title":"Methods Mol Biol"},{"key":"9601_CR84","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/978-1-0716-3255-0_9","volume":"2678","author":"R Lamy","year":"2023","unstructured":"Lamy R, Ma\u2019ayeh S, Chlamydas S, Stewart JM. Proximity extension assay (PEA) platform to detect vitreous biomarkers of diabetic retinopathy. Methods Mol Biol. 2023;2678:135\u201345.","journal-title":"Methods Mol Biol"},{"key":"9601_CR85","doi-asserted-by":"publisher","first-page":"100168","DOI":"10.1016\/j.mcpro.2021.100168","volume":"20","author":"L Wik","year":"2021","unstructured":"Wik L, Nordberg N, Broberg J, Bj\u00f6rkesten J, Assarsson E, Henriksson S, et al. Proximity Extension Assay in Combination with Next-Generation Sequencing for High-throughput Proteome-wide Analysis. Mol Cell Proteom. 2021;20:100168.","journal-title":"Mol Cell Proteom"},{"issue":"12","key":"9601_CR86","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.1021\/acs.jproteome.4c00667","volume":"23","author":"J Candia","year":"2024","unstructured":"Candia J, Fantoni G, Delgado-Peraza F, Shehadeh N, Tanaka T, Moaddel R, et al. Variability of 7K and 11K SomaScan Plasma Proteomics Assays. J Proteome Res. 2024;23(12):5531\u20139.","journal-title":"J Proteome Res"},{"issue":"1","key":"9601_CR87","first-page":"30","volume":"69","author":"L Tagliazucchi","year":"2026","unstructured":"Tagliazucchi L, Costi MP. Mass spectrometry proteomics: a key to faster drug discovery. J Med Chem. 2026;69(1):30\u201371.","journal-title":"J Med Chem"},{"key":"9601_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2023.113472","volume":"517","author":"A Cox","year":"2023","unstructured":"Cox A, Stevens M, Kallon D, Gupta A, White E. Comparative evaluation of Luminex based assays for detection of SARS-CoV-2 antibodies in a transplantation laboratory. J Immunol Methods. 2023;517:113472.","journal-title":"J Immunol Methods"},{"issue":"4","key":"9601_CR89","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2016.04.019","volume":"165","author":"MH Spitzer","year":"2016","unstructured":"Spitzer MH, Nolan GP. Mass cytometry: single cells, many features. Cell. 2016;165(4):780\u201391.","journal-title":"Cell"},{"issue":"7","key":"9601_CR90","doi-asserted-by":"publisher","first-page":"100680","DOI":"10.1016\/j.xcrm.2022.100680","volume":"3","author":"D Feyaerts","year":"2022","unstructured":"Feyaerts D, H\u00e9dou J, Gillard J, Chen H, Tsai ES, Peterson LS, et al. Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19. Cell Rep Med. 2022;3(7):100680.","journal-title":"Cell Rep Med"},{"issue":"6030","key":"9601_CR91","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1126\/science.1198704","volume":"332","author":"SC Bendall","year":"2011","unstructured":"Bendall SC, Simonds EF, Qiu P, Amir el AD, Krutzik PO, Finck R, et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science. 2011;332(6030):687\u201396.","journal-title":"Science"},{"issue":"7","key":"9601_CR92","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.immuni.2022.06.004","volume":"55","author":"CE Burnett","year":"2022","unstructured":"Burnett CE, Okholm TLH, Tenvooren I, Marquez DM, Tamaki S, Munoz Sandoval P, et al. Mass cytometry reveals a conserved immune trajectory of recovery in hospitalized COVID-19 patients. Immunity. 2022;55(7):1284\u2013e983.","journal-title":"Immunity"},{"issue":"5\u20136","key":"9601_CR93","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/prca.201300020","volume":"7","author":"L Martens","year":"2013","unstructured":"Martens L. Bringing proteomics into the clinic: the need for the field to finally take itself seriously. Proteomics Clin Appl. 2013;7(5\u20136):388\u201391.","journal-title":"Proteomics Clin Appl"},{"issue":"5","key":"9601_CR94","first-page":"425","volume":"7","author":"JD Roh","year":"2022","unstructured":"Roh JD, Kitchen RR, Guseh JS, McNeill JN, Aid M, Martinot AJ, et al. Plasma proteomics of COVID-19\u2013associated cardiovascular complications. JACC: Basic to Translational Science. 2022;7(5):425\u201341.","journal-title":"JACC: Basic to Translational Science"},{"key":"9601_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19015-1","author":"F Avila Cobos","year":"2020","unstructured":"Avila Cobos F, Alquicira-Hernandez J, Powell JE, Mestdagh P, De Preter K. Benchmarking of cell type deconvolution pipelines for transcriptomics data. Nat Commun. 2020. https:\/\/doi.org\/10.1038\/s41467-020-19015-1.","journal-title":"Nat Commun"},{"key":"9601_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-02126-9","author":"AE Teschendorff","year":"2020","unstructured":"Teschendorff AE, Zhu T, Breeze CE, Beck S. EPISCORE: cell type deconvolution of bulk tissue DNA methylomes from single-cell RNA-Seq data. Genome Biol. 2020. https:\/\/doi.org\/10.1186\/s13059-020-02126-9.","journal-title":"Genome Biol"},{"issue":"1","key":"9601_CR97","first-page":"1","volume":"19","author":"T Valikangas","year":"2018","unstructured":"Valikangas T, Suomi T, Elo LL. A systematic evaluation of normalization methods in quantitative label-free proteomics. Brief Bioinform. 2018;19(1):1\u201311.","journal-title":"Brief Bioinform"},{"issue":"6","key":"9601_CR98","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/bioinformatics\/bts022","volume":"28","author":"S Chakraborty","year":"2012","unstructured":"Chakraborty S, Datta S, Datta S. Surrogate variable analysis using partial least squares (SVA-PLS) in gene expression studies. Bioinformatics. 2012;28(6):799\u2013806.","journal-title":"Bioinformatics"},{"issue":"1","key":"9601_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47899-w","volume":"15","author":"H Peng","year":"2024","unstructured":"Peng H, Wang H, Kong W, Li J, Goh WWB. Optimizing differential expression analysis for proteomics data via high-performing rules and ensemble inference. Nat Commun. 2024;15(1):3922.","journal-title":"Nat Commun"},{"issue":"7","key":"9601_CR100","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"9601_CR101","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nprot.2011.457","volume":"7","author":"O Stegle","year":"2012","unstructured":"Stegle O, Parts L, Piipari M, Winn J, Durbin R. Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses. Nat Protoc. 2012;7(3):500\u20137.","journal-title":"Nat Protoc"},{"key":"9601_CR102","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.euprot.2015.02.002","volume":"7","author":"K Kammers","year":"2015","unstructured":"Kammers K, Cole RN, Tiengwe C, Ruczinski I. Detecting significant changes in protein abundance. EuPA Open Proteomics. 2015;7:11\u20139.","journal-title":"EuPA Open Proteomics"},{"key":"9601_CR103","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-1-4939-3106-4_7","volume":"1362","author":"S Aggarwal","year":"2016","unstructured":"Aggarwal S, Yadav AK. False discovery rate estimation in proteomics. Methods Mol Biol. 2016;1362:119\u201328.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"9601_CR104","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13059-019-1716-1","volume":"20","author":"K Korthauer","year":"2019","unstructured":"Korthauer K, Kimes PK, Duvallet C, Reyes A, Subramanian A, Teng M, et al. A practical guide to methods controlling false discoveries in computational biology. Genome Biol. 2019;20(1):118.","journal-title":"Genome Biol"},{"key":"9601_CR105","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243\u201359.","journal-title":"Methods Mol Biol"},{"issue":"7","key":"9601_CR106","doi-asserted-by":"publisher","first-page":"e0132813","DOI":"10.1371\/journal.pone.0132813","volume":"10","author":"X Li","year":"2015","unstructured":"Li X, Shen L, Shang X, Liu W. Subpathway analysis based on signaling-pathway impact analysis of signaling pathway. PLoS One. 2015;10(7):e0132813.","journal-title":"PLoS One"},{"issue":"1","key":"9601_CR107","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/bioinformatics\/btn577","volume":"25","author":"AL Tarca","year":"2009","unstructured":"Tarca AL, Draghici S, Khatri P, Hassan SS, Mittal P, Kim JS, et al. A novel signaling pathway impact analysis. Bioinformatics. 2009;25(1):75\u201382.","journal-title":"Bioinformatics"},{"key":"9601_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00535","author":"JS Hawe","year":"2019","unstructured":"Hawe JS, Theis FJ, Heinig M. Inferring interaction networks from multi-omics data. Front Genet. 2019. https:\/\/doi.org\/10.3389\/fgene.2019.00535.","journal-title":"Front Genet"},{"issue":"D1","key":"9601_CR109","doi-asserted-by":"publisher","first-page":"D457","DOI":"10.1093\/nar\/gkv1070","volume":"44","author":"M Kanehisa","year":"2016","unstructured":"Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016;44(D1):D457\u201362.","journal-title":"Nucleic Acids Res"},{"issue":"7414","key":"9601_CR110","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature11247","volume":"489","author":"EP Consortium","year":"2012","unstructured":"Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57\u201374.","journal-title":"Nature"},{"key":"9601_CR111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004085","author":"RF Murphy","year":"2015","unstructured":"Murphy RF, Kutmon M, van Iersel MP, Bohler A, Kelder T, Nunes N, et al. PathVisio 3: an extendable pathway analysis toolbox. PLoS Comput Biol. 2015. https:\/\/doi.org\/10.1371\/journal.pcbi.1004085.","journal-title":"PLoS Comput Biol"},{"key":"9601_CR112","doi-asserted-by":"publisher","DOI":"10.1007\/s41109-022-00444-4","author":"E Kotelnikova","year":"2022","unstructured":"Kotelnikova E, Frahm KM, Lages J, Shepelyansky DL. Statistical properties of the MetaCore network of protein\u2013protein interactions. Appl Netw Sci. 2022. https:\/\/doi.org\/10.1007\/s41109-022-00444-4.","journal-title":"Appl Netw Sci"},{"issue":"D1","key":"9601_CR113","doi-asserted-by":"publisher","first-page":"D661","DOI":"10.1093\/nar\/gkx1064","volume":"46","author":"DN Slenter","year":"2018","unstructured":"Slenter DN, Kutmon M, Hanspers K, Riutta A, Windsor J, Nunes N, et al. WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research. Nucleic Acids Res. 2018;46(D1):D661\u20137.","journal-title":"Nucleic Acids Res"},{"key":"9601_CR114","doi-asserted-by":"crossref","unstructured":"Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A et al. The reactome pathway knowledgebase. Nucleic Acids Res. 2019;48(D1):D498-503.","DOI":"10.1093\/nar\/gkz1031"},{"issue":"90001","key":"9601_CR115","doi-asserted-by":"publisher","first-page":"D535","DOI":"10.1093\/nar\/gkj109","volume":"34","author":"C Stark","year":"2006","unstructured":"Stark C. BioGRID: a general repository for interaction datasets. Nucleic Acids Res. 2006;34(90001):D535\u20139.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"9601_CR116","doi-asserted-by":"publisher","first-page":"D412","DOI":"10.1093\/nar\/gkn760","volume":"37","author":"LJ Jensen","year":"2009","unstructured":"Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, et al. STRING 8\u2013a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 2009;37(Database issue):D412\u20136.","journal-title":"Nucleic Acids Res"},{"key":"9601_CR117","doi-asserted-by":"crossref","unstructured":"Ahsan S, Dr\u0103ghici S. Identifying Significantly Impacted Pathways and Putative Mechanisms with iPathwayGuide. Curr Protocols Bioinf. 2017;57(1):7.15.1-7.15.30.","DOI":"10.1002\/cpbi.24"},{"key":"9601_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85544-4","author":"C Ogris","year":"2021","unstructured":"Ogris C, Hu Y, Arloth J, M\u00fcller NS. Versatile knowledge guided network inference method for prioritizing key regulatory factors in multi-omics data. Sci Rep. 2021;11:6806. https:\/\/doi.org\/10.1038\/s41598-021-85544-4.","journal-title":"Sci Rep"},{"issue":"D1","key":"9601_CR119","doi-asserted-by":"publisher","first-page":"D480","DOI":"10.1093\/nar\/gkaa1100","volume":"49","author":"UniProt C","year":"2021","unstructured":"UniProt C. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res. 2021;49(D1):D480\u20139.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"9601_CR120","doi-asserted-by":"publisher","first-page":"D884","DOI":"10.1093\/nar\/gkaa942","volume":"49","author":"KL Howe","year":"2021","unstructured":"Howe KL, Achuthan P, Allen J, Allen J, Alvarez-Jarreta J, Amode MR, et al. Ensembl 2021. Nucleic Acids Res. 2021;49(D1):D884\u201391.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"9601_CR121","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/bioinformatics\/btn615","volume":"25","author":"S Carbon","year":"2009","unstructured":"Carbon S, Ireland A, Mungall CJ, Shu S, Marshall B, Lewis S, et al. AmiGO: online access to ontology and annotation data. Bioinformatics. 2009;25(2):288\u20139.","journal-title":"Bioinformatics"},{"issue":"3","key":"9601_CR122","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cels.2016.02.015","volume":"2","author":"E Geyer Philipp","year":"2016","unstructured":"Geyer Philipp E, Kulak Nils A, Pichler G, Holdt Lesca M, Teupser D, Mann M. Plasma Proteome Profiling to Assess Human Health and Disease. Cell Syst. 2016;2(3):185\u201395.","journal-title":"Cell Syst"},{"issue":"10","key":"9601_CR123","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nmeth1093","volume":"4","author":"T Kocher","year":"2007","unstructured":"Kocher T, Superti-Furga G. Mass spectrometry-based functional proteomics: from molecular machines to protein networks. Nat Methods. 2007;4(10):807\u201315.","journal-title":"Nat Methods"},{"key":"9601_CR124","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/978-1-4939-8814-3_13","volume":"1871","author":"JR O\u2019Neill","year":"2019","unstructured":"O\u2019Neill JR. An overview of mass spectrometry-based methods for functional proteomics. Methods Mol Biol. 2019;1871:179\u201396.","journal-title":"Methods Mol Biol"},{"key":"9601_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/ebm.2025.10308","volume":"250","author":"DD Fraser","year":"2025","unstructured":"Fraser DD, Roy S, Kuruc M, Quintero M, Van Nynatten LR, Cepinskas G, et al. Functional mass spectrometry indicates anti-protease and complement activity increase with COVID-19 severity. Exp Biol Med (Maywood). 2025;250:10308.","journal-title":"Exp Biol Med (Maywood)"},{"key":"9601_CR126","unstructured":"Van der Maaten L, Hinton G. Visualizing data using t-SNE. J Mach Learn Res. 2008;9(11):2579-2605."},{"issue":"7","key":"9601_CR127","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1089\/cmb.2022.0366","volume":"30","author":"HS Lim","year":"2023","unstructured":"Lim HS, Qiu P. Quantifying cell-type-specific differences of single-cell datasets using uniform manifold approximation and projection for dimension reduction and Shapley Additive exPlanations. J Comput Biol. 2023;30(7):738\u201350.","journal-title":"J Comput Biol"},{"key":"9601_CR128","doi-asserted-by":"crossref","unstructured":"McInnes L, Healy J, Melville J, Umap. Uniform manifold approximation and projection for dimension reduction.J Open Source Softw. 2018;3(29):861.","DOI":"10.21105\/joss.00861"},{"issue":"2","key":"9601_CR129","doi-asserted-by":"publisher","first-page":"111","DOI":"10.31887\/DCNS.2018.20.2\/osporns","volume":"20","author":"O Sporns","year":"2018","unstructured":"Sporns O. Graph theory methods: applications in brain networks. Dialogues Clin Neurosci. 2018;20(2):111\u201321.","journal-title":"Dialogues Clin Neurosci"},{"issue":"10","key":"9601_CR130","doi-asserted-by":"publisher","DOI":"10.3390\/computation11100188","volume":"11","author":"K Erciyes","year":"2023","unstructured":"Erciyes K. Graph-theoretical analysis of biological networks: a survey. Computation. 2023;11(10):188.","journal-title":"Computation"},{"key":"9601_CR131","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaf559","author":"Y Liu","year":"2025","unstructured":"Liu Y, Huse J, Kannan K. Expression graph network framework for biomarker discovery. Brief Bioinform. 2025;26(5): bbaf559. https:\/\/doi.org\/10.1093\/bib\/bbaf559.","journal-title":"Brief Bioinform"},{"key":"9601_CR132","unstructured":"Honnibal M, Montani I, Van Landeghem S, Boyd A, spaCy. Industrial-strength Natural Language Processing in Python. 2020."},{"key":"9601_CR133","doi-asserted-by":"crossref","unstructured":"Qi P, Zhang Y, Zhang Y, Bolton J, Manning CD. Stanza: A Python natural language processing toolkit for many human languages. Proc ACL. 2020:101-108.","DOI":"10.18653\/v1\/2020.acl-demos.14"},{"issue":"9","key":"9601_CR134","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1093\/jamia\/ocab090","volume":"28","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhang Y, Qi P, Manning CD, Langlotz CP. Biomedical and clinical English model packages for the Stanza Python NLP library. J Am Med Inform Assoc. 2021;28(9):1892\u20139.","journal-title":"J Am Med Inform Assoc"},{"issue":"8059","key":"9601_CR135","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41586-025-08710-y","volume":"640","author":"H Cui","year":"2025","unstructured":"Cui H, Tejada-Lapuerta A, Brbi\u0107 M, Saez-Rodriguez J, Cristea S, Goodarzi H, et al. Towards multimodal foundation models in molecular cell biology. Nature. 2025;640(8059):623\u201333.","journal-title":"Nature"},{"key":"9601_CR136","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1597351","volume":"16","author":"X Liu","year":"2025","unstructured":"Liu X, Zhang J, Wang X, Teng M, Wang G, Zhou X. Application of artificial intelligence large language models in drug target discovery. Front Pharmacol. 2025;16:1597351.","journal-title":"Front Pharmacol"},{"issue":"6736","key":"9601_CR137","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.ads0018","volume":"387","author":"T Hayes","year":"2025","unstructured":"Hayes T, Rao R, Akin H, Sofroniew NJ, Oktay D, Lin Z, et al. Simulating 500\u00a0million years of evolution with a language model. Science. 2025;387(6736):850\u20138.","journal-title":"Science"},{"issue":"3","key":"9601_CR138","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1021\/acs.jcim.4c01528","volume":"65","author":"G Wang","year":"2025","unstructured":"Wang G, Zhang H, Shao M, Sun S, Cao C. MMPD-DTA: Integrating Multi-Modal Deep Learning with Pocket-Drug Graphs for Drug-Target Binding Affinity Prediction. J Chem Inf Model. 2025;65(3):1615\u201330.","journal-title":"J Chem Inf Model"},{"key":"9601_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.imu.2023.101188","volume":"37","author":"P Wendland","year":"2023","unstructured":"Wendland P, Schmitt V, Zimmermann J, H\u00e4ger L, G\u00f6pel S, Schenkel-H\u00e4ger C, et al. Machine learning models for predicting severe COVID-19 outcomes in hospitals. Informatics in Medicine Unlocked. 2023;37:101188.","journal-title":"Informatics in Medicine Unlocked"},{"issue":"1","key":"9601_CR140","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40001-025-03742-6","volume":"31","author":"Z Cai","year":"2025","unstructured":"Cai Z, Ding S, Gao J. Development and validation of a machine learning-driven framework for differentiating pediatric bronchopneumonia from lobar pneumonia: a multicenter investigation. Eur J Med Res. 2025;31(1):140.","journal-title":"Eur J Med Res"},{"issue":"1","key":"9601_CR141","doi-asserted-by":"publisher","first-page":"e0000007","DOI":"10.1371\/journal.pdig.0000007","volume":"1","author":"V Demichev","year":"2022","unstructured":"Demichev V, Tober-Lau P, Nazarenko T, Lemke O, Kaur Aulakh S, Whitwell HJ, et al. A proteomic survival predictor for COVID-19 patients in intensive care. PLOS Digit Health. 2022;1(1):e0000007.","journal-title":"PLOS Digit Health"},{"issue":"10","key":"9601_CR142","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1021\/acs.molpharmaceut.8b00284","volume":"15","author":"Y Donner","year":"2018","unstructured":"Donner Y, Kazmierczak S, Fortney K. Drug repurposing using deep embeddings of gene expression profiles. Mol Pharm. 2018;15(10):4314\u201325.","journal-title":"Mol Pharm"},{"issue":"1","key":"9601_CR143","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-024-10499-5","volume":"25","author":"W Li","year":"2024","unstructured":"Li W, Ma W, Yang M, Tang X. Drug repurposing based on the DTD-GNN graph neural network: revealing the relationships among drugs, targets and diseases. BMC Genomics. 2024;25(1):584.","journal-title":"BMC Genomics"},{"issue":"6","key":"9601_CR144","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.1007\/s00521-024-10714-0","volume":"37","author":"H Torkey","year":"2025","unstructured":"Torkey H, El-Behery H, Attia A-F, El-Fishawy N. Drug\u2013target interactions prediction based on similarity graph features extraction and deep learning. Neural Comput Appl. 2025;37(6):4303\u201322.","journal-title":"Neural Comput Appl"},{"issue":"3","key":"9601_CR145","doi-asserted-by":"publisher","DOI":"10.1007\/s10462-023-10669-z","volume":"57","author":"M Besharatifard","year":"2024","unstructured":"Besharatifard M, Vafaee F. A review on graph neural networks for predicting synergistic drug combinations. Artif Intell Rev. 2024;57(3):49.","journal-title":"Artif Intell Rev"},{"issue":"Suppl 2","key":"9601_CR146","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-024-02496-1","volume":"24","author":"J Preiss","year":"2024","unstructured":"Preiss J. Using word evolution to predict drug repurposing. BMC Med Inform Decis Mak. 2024;24(Suppl 2):114.","journal-title":"BMC Med Inform Decis Mak"},{"key":"9601_CR147","first-page":"463","volume":"25","author":"DN Sosa","year":"2020","unstructured":"Sosa DN, Derry A, Guo M, Wei E, Brinton C, Altman RB. A literature-based knowledge graph embedding method for identifying drug repurposing opportunities in rare diseases. Pac Symp Biocomput. 2020;25:463\u201374.","journal-title":"Pac Symp Biocomput"},{"issue":"1","key":"9601_CR148","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-95372-5","volume":"15","author":"S He","year":"2025","unstructured":"He S, Zhao X. Drug repositioning model based on knowledge graph embedding. Sci Rep. 2025;15(1):10298.","journal-title":"Sci Rep"},{"issue":"1","key":"9601_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30095-z","volume":"13","author":"MK Islam","year":"2023","unstructured":"Islam MK, Amaya-Ramirez D, Maigret B, Devignes MD, Aridhi S, Smail-Tabbone M. Molecular-evaluated and explainable drug repurposing for COVID-19 using ensemble knowledge graph embedding. Sci Rep. 2023;13(1):3643.","journal-title":"Sci Rep"},{"issue":"1","key":"9601_CR150","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1038\/s41467-023-39301-y","volume":"14","author":"D Bang","year":"2023","unstructured":"Bang D, Lim S, Lee S, Kim S. Biomedical knowledge graph learning for drug repurposing by extending guilt-by-association to multiple layers. Nat Commun. 2023;14(1):3570.","journal-title":"Nat Commun"},{"issue":"1","key":"9601_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-02353-5","volume":"11","author":"K Hsieh","year":"2021","unstructured":"Hsieh K, Wang Y, Chen L, Zhao Z, Savitz S, Jiang X, et al. Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence. Sci Rep. 2021;11(1):23179.","journal-title":"Sci Rep"},{"key":"9601_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2022.105992","volume":"150","author":"S Doshi","year":"2022","unstructured":"Doshi S, Chepuri SP. A computational approach to drug repurposing using graph neural networks. Comput Biol Med. 2022;150:105992.","journal-title":"Comput Biol Med"},{"key":"9601_CR153","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btad748","author":"X Sun","year":"2024","unstructured":"Sun X, Jia X, Lu Z, Tang J, Li M. Drug repositioning with adaptive graph convolutional networks. Bioinformatics. 2024. https:\/\/doi.org\/10.1093\/bioinformatics\/btad748.","journal-title":"Bioinformatics"},{"key":"9601_CR154","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cbpa.2021.06.001","volume":"65","author":"F Urbina","year":"2021","unstructured":"Urbina F, Puhl AC, Ekins S. Recent advances in drug repurposing using machine learning. Curr Opin Chem Biol. 2021;65:74\u201384.","journal-title":"Curr Opin Chem Biol"},{"issue":"1","key":"9601_CR155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.58647\/DRUGREPO.24.1.0004","volume":"1","author":"EB Anokian","year":"2024","unstructured":"Anokian EB, Freeman J, List A, Santamar\u00eda M, Tanoli LP, Bonnin Z. Machine learning and artificial intelligence in drug repurposing\u2014challenges and perspectives. Drug Repurposing. 2024;1(1):1\u20139.","journal-title":"Drug Repurposing"},{"issue":"suppl2","key":"9601_CR156","doi-asserted-by":"publisher","first-page":"R207","DOI":"10.1093\/hmg\/ddi261","volume":"14","author":"W Sad\u00e9e","year":"2005","unstructured":"Sad\u00e9e W, Dai Z. Pharmacogenetics\/genomics and personalized medicine. Hum Mol Genet. 2005;14(suppl2):R207\u201314.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"9601_CR157","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2018","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2018;18(1):41\u201358.","journal-title":"Nat Rev Drug Discov"},{"key":"9601_CR158","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-6-80","author":"HS Lee","year":"2012","unstructured":"Lee HS, Bae T, Lee J-H, Kim DG, Oh YS, Jang Y, et al. Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug. BMC Syst Biol. 2012. https:\/\/doi.org\/10.1186\/1752-0509-6-80.","journal-title":"BMC Syst Biol"},{"key":"9601_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114296","volume":"183","author":"H Yousefi","year":"2021","unstructured":"Yousefi H, Mashouri L, Okpechi SC, Alahari N, Alahari SK. Repurposing existing drugs for the treatment of COVID-19\/SARS-CoV-2 infection: a review describing drug mechanisms of action. Biochem Pharmacol. 2021;183:114296.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"9601_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00417-y","volume":"5","author":"C Loucera","year":"2020","unstructured":"Loucera C, Esteban-Medina M, Rian K, Falco MM, Dopazo J, Pena-Chilet M. Drug repurposing for COVID-19 using machine learning and mechanistic models of signal transduction circuits related to SARS-CoV-2 infection. Signal Transduct Target Ther. 2020;5(1):290.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"9601_CR161","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/infdis\/jiaa789","volume":"223","author":"JR Strich","year":"2021","unstructured":"Strich JR, Ramos-Benitez MJ, Randazzo D, Stein SR, Babyak A, Davey RT, et al. Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic. J Infect Dis. 2021;223(6):981\u20134.","journal-title":"J Infect Dis"},{"issue":"1","key":"9601_CR162","doi-asserted-by":"publisher","first-page":"e491","DOI":"10.1093\/cid\/ciab732","volume":"75","author":"JR Strich","year":"2022","unstructured":"Strich JR, Tian X, Samour M, King CS, Shlobin O, Reger R, et al. Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial. Clin Infect Dis. 2022;75(1):e491\u20138.","journal-title":"Clin Infect Dis"},{"key":"9601_CR163","doi-asserted-by":"crossref","unstructured":"Suvarna K, Biswas D, Pai MG, Acharjee A, Bankar R. P V, et al. COVID-19 plasma deep proteome reveals distinct signatures in severe patients. Research Square; 2020.","DOI":"10.21203\/rs.3.rs-120570\/v2"},{"key":"9601_CR164","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.652799","volume":"12","author":"K Suvarna","year":"2021","unstructured":"Suvarna K, Biswas D, Pai MGJ, Acharjee A, Bankar R, Palanivel V, et al. Proteomics and machine learning approaches reveal a set of prognostic markers for COVID-19 severity with drug repurposing potential. Front Physiol. 2021;12:652799.","journal-title":"Front Physiol"},{"key":"9601_CR165","doi-asserted-by":"publisher","first-page":"105115","DOI":"10.1016\/j.antiviral.2021.105115","volume":"192","author":"T Kashyap","year":"2021","unstructured":"Kashyap T, Murray J, Walker CJ, Chang H, Tamir S, Hou B, et al. Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo. Antiviral Res. 2021;192:105115.","journal-title":"Antiviral Res"},{"key":"9601_CR166","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.884228","volume":"13","author":"G Mostafa-Hedeab","year":"2022","unstructured":"Mostafa-Hedeab G, Al-Kuraishy HM, Al-Gareeb AI, Welson NN, El-Saber Batiha G, Conte-Junior CA. Selinexor and COVID-19: the neglected warden. Front Pharmacol. 2022;13:884228.","journal-title":"Front Pharmacol"},{"key":"9601_CR167","doi-asserted-by":"crossref","unstructured":"Chan M, Vijay S, McElrath MJ, Holland EC, Gujral TS. Machine learning identifies molecular regulators and therapeutics for targeting SARS\u2010CoV2\u2010induced cytokine release Mol Syst Biol. 2021;17(9):e10426.","DOI":"10.15252\/msb.202110426"},{"issue":"1","key":"9601_CR168","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/all.14907","volume":"77","author":"M Plassmeyer","year":"2022","unstructured":"Plassmeyer M, Alpan O, Corley MJ, Premeaux TA, Lillard K, Coatney P, et al. Caspases and therapeutic potential of caspase inhibitors in moderate-severe SARS-CoV-2 infection and long COVID. Allergy. 2022;77(1):118\u201329.","journal-title":"Allergy"},{"key":"9601_CR169","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1016\/j.csbj.2021.05.037","volume":"19","author":"A Rajput","year":"2021","unstructured":"Rajput A, Thakur A, Mukhopadhyay A, Kamboj S, Rastogi A, Gautam S, et al. Prediction of repurposed drugs for Coronaviruses using artificial intelligence and machine learning. Comput Struct Biotechnol J. 2021;19:3133\u201348.","journal-title":"Comput Struct Biotechnol J"},{"issue":"10285","key":"9601_CR170","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"RC Group","year":"2021","unstructured":"Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637\u201345.","journal-title":"Lancet"},{"issue":"15","key":"9601_CR171","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1056\/NEJMc2100217","volume":"384","author":"C Salama","year":"2021","unstructured":"Salama C, Mohan SV. Tocilizumab in patients hospitalized with Covid-19 pneumonia. Reply. N Engl J Med. 2021;384(15):1473\u20134.","journal-title":"N Engl J Med"},{"issue":"6","key":"9601_CR172","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00408-020-00408-4","volume":"198","author":"F Scialo","year":"2020","unstructured":"Scialo F, Daniele A, Amato F, Pastore L, Matera MG, Cazzola M, et al. ACE2: The Major Cell Entry Receptor for SARS-CoV-2. Lung. 2020;198(6):867\u201377.","journal-title":"Lung"},{"issue":"1","key":"9601_CR173","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s42003-023-04860-9","volume":"6","author":"B Havranek","year":"2023","unstructured":"Havranek B, Lindsey GW, Higuchi Y, Itoh Y, Suzuki T, Okamoto T, et al. A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo. Commun Biol. 2023;6(1):513.","journal-title":"Commun Biol"},{"issue":"11","key":"9601_CR174","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202216109","volume":"14","author":"L Zhang","year":"2022","unstructured":"Zhang L, Narayanan KK, Cooper L, Chan KK, Skeeters SS, Devlin CA, et al. An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2. EMBO Mol Med. 2022;14(11):e16109.","journal-title":"EMBO Mol Med"},{"issue":"12","key":"9601_CR175","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.3324\/haematol.2020.260117","volume":"105","author":"R Peffault de Latour","year":"2020","unstructured":"Peffault de Latour R, Bergeron A, Lengline E, Dupont T, Marchal A, Galicier L, et al. Complement C5 inhibition in patients with COVID-19 - a promising target? Haematologica. 2020;105(12):2847\u201350.","journal-title":"Haematologica"},{"issue":"1","key":"9601_CR176","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12931-022-02278-1","volume":"23","author":"EHT Lim","year":"2022","unstructured":"Lim EHT, Vlaar APJ, Bos LDJ, van Vught LA, Boer AMT, Dujardin RWG, et al. Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial. Respir Res. 2022;23(1):375.","journal-title":"Respir Res"},{"issue":"12","key":"9601_CR177","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S2213-2600(22)00297-1","volume":"10","author":"APJ Vlaar","year":"2022","unstructured":"Vlaar APJ, Witzenrath M, van Paassen P, Heunks LMA, Mourvillier B, de Bruin S, et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022;10(12):1137\u201346.","journal-title":"Lancet Respir Med"},{"issue":"11","key":"9601_CR178","doi-asserted-by":"publisher","DOI":"10.1007\/s13205-022-03363-4","volume":"12","author":"NB Prabhu","year":"2022","unstructured":"Prabhu NB, Vinay CM, Satyamoorthy K, Rai PS. Pharmacogenomics deliberations of 2-deoxy-d-glucose in the treatment of COVID-19 disease: an in silico approach. 3 Biotech. 2022;12(11):287.","journal-title":"3 Biotech"},{"issue":"7","key":"9601_CR179","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1021\/acs.jcim.2c01641","volume":"63","author":"O Garland","year":"2023","unstructured":"Garland O, Ton AT, Moradi S, Smith JR, Kovacic S, Ng K, et al. Large-Scale Virtual Screening for the Discovery of SARS-CoV-2 Papain-like Protease (PLpro) Non-covalent Inhibitors. J Chem Inf Model. 2023;63(7):2158\u201369.","journal-title":"J Chem Inf Model"},{"issue":"7","key":"9601_CR180","first-page":"780","volume":"27","author":"E Emadi","year":"2024","unstructured":"Emadi E, Hamidi Alamdari D, Attaran D, Attaran S. Application of methylene blue for the prevention and treatment of COVID-19: a narrative review. Iran J Basic Med Sci. 2024;27(7):780\u201392.","journal-title":"Iran J Basic Med Sci"},{"key":"9601_CR181","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ddtec.2021.06.004","volume":"39","author":"A Mukherjee","year":"2021","unstructured":"Mukherjee A, Verma A, Bihani S, Burli A, Mantri K, Srivastava S. Proteomics advances towards developing SARS-CoV-2 therapeutics using in silico drug repurposing approaches. Drug Discov Today Technol. 2021;39:1\u201312.","journal-title":"Drug Discov Today Technol"},{"key":"9601_CR182","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.628144","author":"BM Sahoo","year":"2021","unstructured":"Sahoo BM, Ravi Kumar BVV, Sruti J, Mahapatra MK, Banik BK, Borah P. Drug repurposing strategy (DRS): emerging approach to identify potential therapeutics for treatment of novel coronavirus infection. Front Mol Biosci. 2021. https:\/\/doi.org\/10.3389\/fmolb.2021.628144.","journal-title":"Front Mol Biosci"},{"key":"9601_CR183","unstructured":"Chippa V, Aleem A, Anjum F. Postacute Coronavirus (COVID-19) Syndrome. StatPearls. Treasure Island (FL)2025."},{"key":"9601_CR184","doi-asserted-by":"crossref","unstructured":"Marshall GD Jr. The pathophysiology of postacute sequelae of COVID-19 (PASC): possible role for persistent inflammation. Asia Pac Allergy. 2023;13(2):77\u201384.","DOI":"10.5415\/apallergy.0000000000000106"},{"issue":"6","key":"9601_CR185","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/14787210.2021.1851195","volume":"19","author":"P Shende","year":"2021","unstructured":"Shende P, Khanolkar B, Gaud RS. Drug repurposing: new strategies for addressing COVID-19 outbreak. Expert Rev Anti Infect Ther. 2021;19(6):689\u2013706.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"10","key":"9601_CR186","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1177\/2472555220942123","volume":"25","author":"W Zhu","year":"2020","unstructured":"Zhu W, Chen CZ, Gorshkov K, Xu M, Lo DC, Zheng W. RNA-Dependent RNA polymerase as a target for COVID-19 drug discovery. SLAS Discov. 2020;25(10):1141\u201351.","journal-title":"SLAS Discov"},{"key":"9601_CR187","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1582783","volume":"16","author":"KP Michalak","year":"2025","unstructured":"Michalak KP, Michalak AZ, Brenk-Krakowska A. Acute COVID-19 and LongCOVID syndrome - molecular implications for therapeutic strategies - review. Front Immunol. 2025;16:1582783.","journal-title":"Front Immunol"},{"key":"9601_CR188","doi-asserted-by":"publisher","first-page":"1130828","DOI":"10.3389\/fphar.2023.1130828","volume":"14","author":"SO Bello","year":"2023","unstructured":"Bello SO, Yunusa A, Adamu AA, Imam MU, Bello MB, Shuaibu A, et al. Innovative, rapid, high-throughput method for drug repurposing in a pandemic-A case study of SARS-CoV-2 and COVID-19. Front Pharmacol. 2023;14:1130828.","journal-title":"Front Pharmacol"},{"issue":"12","key":"9601_CR189","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/infdis\/jiad324","volume":"228","author":"D Paraskevis","year":"2023","unstructured":"Paraskevis D, Gkova M, Mellou K, Gerolymatos G, Psalida N, Gkolfinopoulou K, et al. Real-world Effectiveness of Molnupiravir and Nirmatrelvir\/Ritonavir as Treatments for COVID-19 in Patients at High Risk. J Infect Dis. 2023;228(12):1667\u201374.","journal-title":"J Infect Dis"},{"issue":"1","key":"9601_CR190","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1038\/s41467-025-57905-4","volume":"16","author":"SMB Calleja","year":"2025","unstructured":"Calleja SMB, Devine DJ, Kuchel SM, Lu NW, Wu BGC. A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID. Nat Commun. 2025;16(1):2900.","journal-title":"Nat Commun"},{"issue":"6685","key":"9601_CR191","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1126\/science.adl0867","volume":"383","author":"Z Al-Aly","year":"2024","unstructured":"Al-Aly Z, Topol E. Solving the puzzle of long covid. Science. 2024;383(6685):830\u20132.","journal-title":"Science"},{"key":"9601_CR192","unstructured":"LC-REVITALIZE - A Long COVID Repurposed Drug Study [Internet]. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06928272"},{"issue":"21","key":"9601_CR193","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1001\/jama.2020.22240","volume":"324","author":"WH Self","year":"2020","unstructured":"Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020;324(21):2165\u201376.","journal-title":"JAMA"},{"issue":"14","key":"9601_CR194","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1001\/jama.2021.3071","volume":"325","author":"E L\u00f3pez-Medina","year":"2021","unstructured":"L\u00f3pez-Medina E, L\u00f3pez P, Hurtado IC, D\u00e1valos DM, Ramirez O, Mart\u00ednez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. JAMA. 2021;325(14):1426\u201335.","journal-title":"JAMA"},{"issue":"24","key":"9601_CR195","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","volume":"383","author":"JH Stone","year":"2020","unstructured":"Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with covid-19. N Engl J Med. 2020;383(24):2333\u201344.","journal-title":"N Engl J Med"},{"issue":"6","key":"9601_CR196","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"WHOST Consortium","year":"2021","unstructured":"Consortium WHOST, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):497\u2013511.","journal-title":"N Engl J Med"},{"issue":"10","key":"9601_CR197","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1513\/AnnalsATS.202005-566FR","volume":"17","author":"H Farne","year":"2020","unstructured":"Farne H, Kumar K, Ritchie AI, Finney LJ, Johnston SL, Singanayagam A. Repurposing existing drugs for the treatment of COVID-19. Ann Am Thorac Soc. 2020;17(10):1186\u201394.","journal-title":"Ann Am Thorac Soc"},{"key":"9601_CR198","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12122750","author":"G Molla","year":"2024","unstructured":"Molla G, Bitew M. Revolutionizing personalized medicine: synergy with multi-omics data generation, main hurdles, and future perspectives. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12122750.","journal-title":"Biomedicines"},{"issue":"7","key":"9601_CR199","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13763","volume":"52","author":"R Ferreira-da-Silva","year":"2022","unstructured":"Ferreira-da-Silva R, Ribeiro-Vaz I, Morato M, Junqueira Pol\u00f3nia J. A comprehensive review of adverse events to drugs used in COVID-19 patients: recent clinical evidence. Eur J Clin Invest. 2022;52(7):e13763.","journal-title":"Eur J Clin Invest"},{"key":"9601_CR200","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11060475","author":"J Dopazo","year":"2021","unstructured":"Dopazo J, Maya-Miles D, Garc\u00eda F, Lorusso N, Calleja M, Pareja MJ, et al. Implementing personalized medicine in COVID-19 in Andalusia: an opportunity to transform the healthcare system. J Pers Med. 2021. https:\/\/doi.org\/10.3390\/jpm11060475.","journal-title":"J Pers Med"},{"issue":"10","key":"9601_CR201","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1021\/jasms.0c00238","volume":"31","author":"I Mahmud","year":"2020","unstructured":"Mahmud I, Garrett TJ. Mass spectrometry techniques in emerging pathogens studies: COVID-19 perspectives. J Am Soc Mass Spectrom. 2020;31(10):2013\u201324.","journal-title":"J Am Soc Mass Spectrom"},{"issue":"1","key":"9601_CR202","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22767-z","volume":"12","author":"W Zhong","year":"2021","unstructured":"Zhong W, Edfors F, Gummesson A, Bergstr\u00f6m G, Fagerberg L, Uhl\u00e9n M. Next generation plasma proteome profiling to monitor health and disease. Nat Commun. 2021;12(1):2493.","journal-title":"Nat Commun"},{"key":"9601_CR203","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.bbi.2023.08.022","volume":"114","author":"BA Hanson","year":"2023","unstructured":"Hanson BA, Visvabharathy L, Orban ZS, Jimenez M, Batra A, Liotta EM, et al. Plasma proteomics show altered inflammatory and mitochondrial proteins in patients with neurologic symptoms of post-acute sequelae of SARS-CoV-2 infection. Brain Behav Immun. 2023;114:462\u201374.","journal-title":"Brain Behav Immun"},{"issue":"7","key":"9601_CR204","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100680","volume":"3","author":"D Feyaerts","year":"2022","unstructured":"Feyaerts D, Hedou J, Gillard J, Chen H, Tsai ES, Peterson LS, et al. Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19. Cell Rep Med. 2022;3(7):100680.","journal-title":"Cell Rep Med"},{"key":"9601_CR205","doi-asserted-by":"crossref","unstructured":"Das S, Dunbar S. Multiplex Immunoassay Approaches Using Luminex\u00ae xMAP\u00ae Technology for the Study of COVID-19 Disease. In: Guest PC, editor. Application of omic techniques to identify new biomarkers and drug targets for COVID-19. Cham: Springer International Publishing; 2023. p. 479\u201389.","DOI":"10.1007\/978-3-031-28012-2_26"},{"key":"9601_CR206","doi-asserted-by":"publisher","first-page":"842740","DOI":"10.3389\/fimmu.2022.842740","volume":"13","author":"TA Premeaux","year":"2022","unstructured":"Premeaux TA, Yeung ST, Bukhari Z, Bowler S, Alpan O, Gupta R, et al. Emerging Insights on Caspases in COVID-19 Pathogenesis, Sequelae, and Directed Therapies. Front Immunol. 2022;13:842740.","journal-title":"Front Immunol"},{"issue":"2","key":"9601_CR207","doi-asserted-by":"publisher","first-page":"307","DOI":"10.4049\/jimmunol.2000513","volume":"205","author":"JKY Yap","year":"2020","unstructured":"Yap JKY, Moriyama M, Iwasaki A. Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19. J Immunol. 2020;205(2):307\u201312.","journal-title":"J Immunol"},{"issue":"11","key":"9601_CR208","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41577-021-00588-x","volume":"21","author":"SM Vora","year":"2021","unstructured":"Vora SM, Lieberman J, Wu H. Inflammasome activation at the crux of severe COVID-19. Nat Rev Immunol. 2021;21(11):694\u2013703.","journal-title":"Nat Rev Immunol"},{"key":"9601_CR209","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2021.106539","volume":"154","author":"MAR Ripon","year":"2021","unstructured":"Ripon MAR, Bhowmik DR, Amin MT, Hossain MS. Role of arachidonic cascade in COVID-19 infection: A review. Prostaglandins Other Lipid Mediat. 2021;154:106539.","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"1","key":"9601_CR210","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3390\/cimb45010023","volume":"45","author":"\u00c9P Zambalde","year":"2022","unstructured":"Zambalde \u00c9P, Dias TL, Maktura GC, Amorim MR, Brenha B, Santos LN, et al. Increased mTOR Signaling and Impaired Autophagic Flux Are Hallmarks of SARS-CoV-2 Infection. Curr Issues Mol Biol. 2022;45(1):327\u201336.","journal-title":"Curr Issues Mol Biol"},{"key":"9601_CR211","doi-asserted-by":"publisher","first-page":"791267","DOI":"10.3389\/fimmu.2022.791267","volume":"13","author":"J Dai","year":"2022","unstructured":"Dai J, Wang H, Liao Y, Tan L, Sun Y, Song C, et al. Coronavirus Infection and Cholesterol Metabolism. Front Immunol. 2022;13:791267.","journal-title":"Front Immunol"},{"issue":"14","key":"9601_CR212","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21145168","volume":"21","author":"C Grobler","year":"2020","unstructured":"Grobler C, Maphumulo SC, Grobbelaar LM, Bredenkamp JC, Laubscher GJ, Lourens PJ, et al. Covid-19: The Rollercoaster of Fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-Selectin and Their Interactions with Endothelial Cells, Platelets and Erythrocytes. Int J Mol Sci. 2020;21(14):5168.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"9601_CR213","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.medj.2024.01.011","volume":"5","author":"K Baillie","year":"2024","unstructured":"Baillie K, Davies HE, Keat SBK, Ladell K, Miners KL, Jones SA, et al. Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID. Med. 2024;5(3):239-53.e5.","journal-title":"Med"},{"issue":"12","key":"9601_CR214","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.chom.2024.11.007","volume":"32","author":"Z Rong","year":"2024","unstructured":"Rong Z, Mai H, Ebert G, Kapoor S, Puelles VG, Czogalla J, et al. Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19. Cell Host Microbe. 2024;32(12):2112\u2013e3010.","journal-title":"Cell Host Microbe"},{"issue":"3","key":"9601_CR215","doi-asserted-by":"publisher","first-page":"L430","DOI":"10.1152\/ajplung.00499.2020","volume":"320","author":"R Abdel Hameid","year":"2021","unstructured":"Abdel Hameid R, Cormet-Boyaka E, Kuebler WM, Uddin M, Berdiev BK. SARS-CoV-2 may hijack GPCR signaling pathways to dysregulate lung ion and fluid transport. Am J Physiol Lung Cell Mol Physiol. 2021;320(3):L430\u20135.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"9601_CR216","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26094202","author":"FPG da Silva","year":"2025","unstructured":"da Silva FPG, Matte R, Wiedmer DB, da Silva APG, Menin RM, Barbosa FB, et al. HIF-1\u03b1 pathway in COVID-19: a scoping review of its modulation and related treatments. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26094202.","journal-title":"Int J Mol Sci"},{"key":"9601_CR217","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26226945","author":"G El-Arif","year":"2021","unstructured":"El-Arif G, Farhat A, Khazaal S, Annweiler C, Kovacic H, Wu Y, et al. The renin-angiotensin system: a key role in SARS-CoV-2-induced COVID-19. Molecules. 2021. https:\/\/doi.org\/10.3390\/molecules26226945.","journal-title":"Molecules"},{"key":"9601_CR218","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2021.685196","volume":"9","author":"AF Santos","year":"2021","unstructured":"Santos AF, P\u00f3voa P, Paix\u00e3o P, Mendon\u00e7a A, Taborda-Barata L. Changes in Glycolytic Pathway in SARS-COV 2 Infection and Their Importance in Understanding the Severity of COVID-19. Front Chem. 2021;9:685196.","journal-title":"Front Chem"},{"key":"9601_CR219","doi-asserted-by":"publisher","DOI":"10.3390\/v14061247","author":"M Znaidia","year":"2022","unstructured":"Znaidia M, Demeret C, van der Werf S, Komarova AV. Characterization of SARS-CoV-2 evasion: interferon pathway and therapeutic options. Viruses. 2022. https:\/\/doi.org\/10.3390\/v14061247.","journal-title":"Viruses"},{"key":"9601_CR220","doi-asserted-by":"publisher","DOI":"10.3390\/cells11020306","author":"JD Ravid","year":"2022","unstructured":"Ravid JD, Leiva O, Chitalia VC. Janus kinase signaling pathway and its role in COVID-19 inflammatory, vascular, and thrombotic manifestations. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11020306.","journal-title":"Cells"},{"key":"9601_CR221","doi-asserted-by":"publisher","DOI":"10.3390\/biology12060843","author":"R Salom\u00e3o","year":"2023","unstructured":"Salom\u00e3o R, Assis V, de Sousa Neto IV, Petriz B, Babault N, Durigan JLQ, et al. Involvement of matrix metalloproteinases in COVID-19: molecular targets, mechanisms, and insights for therapeutic interventions. Biology. 2023. https:\/\/doi.org\/10.3390\/biology12060843.","journal-title":"Biology"},{"issue":"7","key":"9601_CR222","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107118","volume":"26","author":"A Mozzi","year":"2023","unstructured":"Mozzi A, Oldani M, Forcella ME, Vantaggiato C, Cappelletti G, Pontremoli C, et al. SARS-CoV-2 ORF3c impairs mitochondrial respiratory metabolism, oxidative stress, and autophagic flux. iScience. 2023;26(7):107118.","journal-title":"iScience"},{"issue":"12","key":"9601_CR223","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3345\/cep.2024.00941","volume":"67","author":"AE Ahmed","year":"2024","unstructured":"Ahmed AE, Abuhamdah SMA, Hassan MH, Rashwan NI, Abd-Elmawgood EA, Mansour H, et al. Clinical, biochemical, and genetic study of TACE\/TNF-\u03b1\/ACE signaling pathway in pediatric COVID-19 infection. Clin Exp Pediatr. 2024;67(12):704\u201317.","journal-title":"Clin Exp Pediatr"},{"key":"9601_CR224","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.csbj.2021.01.034","volume":"19","author":"BA Khalil","year":"2021","unstructured":"Khalil BA, Elemam NM, Maghazachi AA. Chemokines and chemokine receptors during COVID-19 infection. Comput Struct Biotechnol J. 2021;19:976\u201388.","journal-title":"Comput Struct Biotechnol J"},{"key":"9601_CR225","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2022.102252","volume":"78","author":"G Liu","year":"2022","unstructured":"Liu G, Gack MU. Insights into pandemic respiratory viruses: manipulation of the antiviral interferon response by SARS-CoV-2 and influenza A virus. Curr Opin Immunol. 2022;78:102252.","journal-title":"Curr Opin Immunol"},{"issue":"26","key":"9601_CR226","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2122897119","volume":"119","author":"C Qin","year":"2022","unstructured":"Qin C, Rao Y, Yuan H, Wang TY, Zhao J, Espinosa B, et al. SARS-CoV-2 couples evasion of inflammatory response to activated nucleotide synthesis. Proc Natl Acad Sci U S A. 2022;119(26):e2122897119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"9601_CR227","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s12291-023-01121-8","volume":"38","author":"A Bansal","year":"2023","unstructured":"Bansal A, Kumar S, Rai N, Kumari S, Kumar V, Kumar A, et al. A Pilot Study on Blood Components in COVID-19 Affected Subjects: A Correlation to UPR Signalling and ER-Stress. Indian J Clin Biochem. 2023;38(3):374\u201384.","journal-title":"Indian J Clin Biochem"},{"key":"9601_CR228","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.857490","volume":"13","author":"D Zhang","year":"2022","unstructured":"Zhang D, Zhu L, Wang Y, Li P, Gao Y. Translational Control of COVID-19 and Its Therapeutic Implication. Front Immunol. 2022;13:857490.","journal-title":"Front Immunol"},{"issue":"12","key":"9601_CR229","first-page":"e50212","volume":"15","author":"FO Kamel","year":"2023","unstructured":"Kamel FO, Magadmi R, Qutub S, Badawi M, Badawi M, Madani TA, et al. Machine Learning-Based Prediction of COVID-19 Prognosis Using Clinical and Hematologic Data. Cureus. 2023;15(12):e50212.","journal-title":"Cureus"},{"key":"9601_CR230","volume":"36","author":"A Yazdani","year":"2022","unstructured":"Yazdani A, Zahmatkeshan M, Ravangard R, Sharifian R, Shirdeli M. Supervised Machine Learning Approach to COVID-19 Detection Based on Clinical Data. Med J Islam Repub Iran. 2022;36:110.","journal-title":"Med J Islam Repub Iran"},{"issue":"1","key":"9601_CR231","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-69209-6","volume":"14","author":"F Mohtasham","year":"2024","unstructured":"Mohtasham F, Pourhoseingholi M, Hashemi Nazari SS, Kavousi K, Zali MR. Comparative analysis of feature selection techniques for COVID-19 dataset. Sci Rep. 2024;14(1):18627.","journal-title":"Sci Rep"},{"key":"9601_CR232","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12092144","author":"KR Islam","year":"2022","unstructured":"Islam KR, Kumar J, Tan TL, Reaz MBI, Rahman T, Khandakar A, et al. Prognostic model of ICU admission risk in patients with COVID-19 infection using machine learning. Diagnostics. 2022. https:\/\/doi.org\/10.3390\/diagnostics12092144.","journal-title":"Diagnostics"},{"issue":"11","key":"9601_CR233","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v13.i11.100966","volume":"13","author":"GR Sridhar","year":"2025","unstructured":"Sridhar GR, Yarabati V, Gumpeny L. Predicting outcomes using neural networks in the intensive care unit. World J Clin Cases. 2025;13(11):100966.","journal-title":"World J Clin Cases"},{"key":"9601_CR234","doi-asserted-by":"publisher","DOI":"10.3390\/biology10111174","author":"S Akter","year":"2021","unstructured":"Akter S, Shamrat F, Chakraborty S, Karim A, Azam S. COVID-19 detection using deep learning algorithm on chest X-ray images. Biology. 2021. https:\/\/doi.org\/10.3390\/biology10111174.","journal-title":"Biology"},{"key":"9601_CR235","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12103446","author":"MH Lee","year":"2023","unstructured":"Lee MH, Shomanov A, Kudaibergenova M, Viderman D. Deep learning methods for interpretation of pulmonary CT and X-ray images in patients with COVID-19-related lung involvement: a systematic review. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12103446.","journal-title":"J Clin Med"},{"key":"9601_CR236","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2023.106619","volume":"154","author":"FH Yagin","year":"2023","unstructured":"Yagin FH, Cicek \u0130B, Alkhateeb A, Yagin B, Colak C, Azzeh M, et al. Explainable artificial intelligence model for identifying COVID-19 gene biomarkers. Comput Biol Med. 2023;154:106619.","journal-title":"Comput Biol Med"},{"issue":"1","key":"9601_CR237","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1038\/s41598-023-31542-7","volume":"13","author":"M Laatifi","year":"2023","unstructured":"Laatifi M, Douzi S, Ezzine H, Asry CE, Naya A, Bouklouze A, et al. Explanatory predictive model for COVID-19 severity risk employing machine learning, shapley addition, and LIME. Sci Rep. 2023;13(1):5481.","journal-title":"Sci Rep"},{"key":"9601_CR238","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.neucom.2021.10.035","volume":"468","author":"MO Alassafi","year":"2022","unstructured":"Alassafi MO, Jarrah M, Alotaibi R. Time series predicting of COVID-19 based on deep learning. Neurocomputing (Amst). 2022;468:335\u201344.","journal-title":"Neurocomputing (Amst)"},{"issue":"3","key":"9601_CR239","doi-asserted-by":"publisher","first-page":"599","DOI":"10.4049\/jimmunol.2000981","volume":"206","author":"J Tian","year":"2021","unstructured":"Tian J, Zhang M, Jin M, Zhang F, Chu Q, Wang X, et al. Repurposed tocilizumab in patients with severe COVID-19. J Immunol. 2021;206(3):599\u2013606.","journal-title":"J Immunol"},{"key":"9601_CR240","doi-asserted-by":"publisher","DOI":"10.3390\/ph14070680","author":"M Saber-Ayad","year":"2021","unstructured":"Saber-Ayad M, Hammoudeh S, Abu-Gharbieh E, Hamoudi R, Tarazi H, Al-Tel TH, et al. Current status of baricitinib as a repurposed therapy for COVID-19. Pharmaceuticals (Basel). 2021. https:\/\/doi.org\/10.3390\/ph14070680.","journal-title":"Pharmaceuticals (Basel)"},{"key":"9601_CR241","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.tma.2023.06.005","volume":"7","author":"J Lee","year":"2023","unstructured":"Lee J. Treatment mechanism of immune triad from the repurposing drug against COVID-19. Transl Med Aging. 2023;7:33\u201345.","journal-title":"Transl Med Aging"},{"issue":"1","key":"9601_CR242","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/bmb\/ldac037","volume":"147","author":"Y Augustin","year":"2023","unstructured":"Augustin Y, Staines HM, Velavan TP, Kamarulzaman A, Kremsner PG, Krishna S. Drug repurposing for COVID-19: current evidence from randomized controlled adaptive platform trials and living systematic reviews. Br Med Bull. 2023;147(1):31\u201349.","journal-title":"Br Med Bull"},{"issue":"3","key":"9601_CR243","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3390\/covid2030028","volume":"2","author":"D-H Cho","year":"2022","unstructured":"Cho D-H, Choi J, Gwon JG. Atorvastatin reduces the severity of COVID-19: a nationwide, total population-based, case-control study. COVID. 2022;2(3):398\u2013406.","journal-title":"COVID"},{"key":"9601_CR244","first-page":"100875","volume":"36","author":"L Davoodi","year":"2021","unstructured":"Davoodi L, Jafarpour H, Oladi Z, Zakariaei Z, Tabarestani M, Ahmadi BM, et al. Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial. Int J Cardiol Heart Vasc. 2021;36:100875.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"9601_CR245","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.830990","volume":"13","author":"B Chatterjee","year":"2022","unstructured":"Chatterjee B, Thakur SS. Remdesivir and its combination with repurposed drugs as COVID-19 therapeutics. Front Immunol. 2022;13:830990.","journal-title":"Front Immunol"},{"issue":"1","key":"9601_CR246","doi-asserted-by":"publisher","DOI":"10.1007\/s44192-023-00036-3","volume":"3","author":"K Hashimoto","year":"2023","unstructured":"Hashimoto K. Overview of the potential use of fluvoxamine for COVID-19 and long COVID. Discov Ment Health. 2023;3(1):9.","journal-title":"Discov Ment Health"},{"key":"9601_CR247","doi-asserted-by":"publisher","first-page":"660490","DOI":"10.3389\/fphar.2021.660490","volume":"12","author":"SP Davies","year":"2021","unstructured":"Davies SP, Mycroft-West CJ, Pagani I, Hill HJ, Chen YH, Karlsson R, et al. The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS-CoV-2 in Cell Culture Models. Front Pharmacol. 2021;12:660490.","journal-title":"Front Pharmacol"},{"issue":"1","key":"9601_CR248","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14787210.2020.1799785","volume":"19","author":"M Infante","year":"2021","unstructured":"Infante M, Ricordi C, Alejandro R, Caprio M, Fabbri A. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. Expert Rev Anti-Infect Ther. 2021;19(1):5\u201316.","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"2","key":"9601_CR249","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106028","volume":"56","author":"S Tripathy","year":"2020","unstructured":"Tripathy S, Dassarma B, Roy S, Chabalala H, Matsabisa MG. A review on possible modes of action of chloroquine\/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. Int J Antimicrob Agents. 2020;56(2):106028.","journal-title":"Int J Antimicrob Agents"},{"key":"9601_CR250","unstructured":"Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04332991"},{"key":"9601_CR251","unstructured":"Efficacy and Safety of Favipiravir in Management of COVID-19 [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04349241"},{"key":"9601_CR252","unstructured":"Phase A 2, Randomized D, Blinded. Placebo Controlled Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild or Asymptomatic COVID-19 [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04346628"},{"key":"9601_CR253","unstructured":"Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04390022"},{"key":"9601_CR254","unstructured":"Administration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO): A Phase I\/II Safety, Tolerability, and Efficacy Clinical Trial [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04357782"},{"key":"9601_CR255","unstructured":"A Phase 1 Randomized Double Blind Placebo Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04461353"},{"key":"9601_CR256","unstructured":"Phase A. 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734\u2122) in Participants With Severe COVID-19 [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04292899"},{"key":"9601_CR257","unstructured":"Multicenter A. Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04280705"},{"key":"9601_CR258","unstructured":"Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19 [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04356937"},{"key":"9601_CR259","unstructured":"The ECLA PHRI COLCOVID Trial [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04328480"},{"key":"9601_CR260","unstructured":"Multi-centre, Adaptive. Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04315948"},{"key":"9601_CR261","unstructured":"Recombinant Human C. 1 Esterase Inhibitor (Ruconest\u00ae) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial in the US [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04530136"},{"key":"9601_CR262","unstructured":"Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04487886"},{"key":"9601_CR263","unstructured":"A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19) [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04425538"},{"key":"9601_CR264","unstructured":"Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19 [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04391179"},{"key":"9601_CR265","unstructured":"Tocilizumab Versus Baricitinib in Hospitalized Patients With Severe COVID-19: an Open-label, Randomized Controlled Trial [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05082714"},{"key":"9601_CR266","unstructured":"Phase A 2, Blind RD. Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients Experiencing Prolonged Coronavirus Disease 2019 (COVID-19) Symptoms [Long-Haulers] [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04678830"}],"container-title":["Clinical Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12014-026-09601-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-026-09601-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12014-026-09601-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T06:03:04Z","timestamp":1778220184000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12014-026-09601-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":266,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["9601"],"URL":"https:\/\/doi.org\/10.1186\/s12014-026-09601-8","relation":{},"ISSN":["1542-6416","1559-0275"],"issn-type":[{"value":"1542-6416","type":"print"},{"value":"1559-0275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='SmallCaps' removed-->Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}